A 12-Week, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of FerShizn on Improving Body Fat of Overweight or Obesity Subject.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007809

Enrollment

100

Registered

2022-10-14

Start date

2022-07-04

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : The study will consist of a Screening Period (up to 14 days), a Treatment Period (12week-End-of-Study Visit within 84 days. Following completive screening procedures and confirma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Male and female subjects, 19-60 years of age 2. BMI of 23-30 kg/m2 3. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1) Stable body weight by subject report (+ 5%) in the previous 3 months prior to Screening 2) Anti-obesity (energy metabolism, appetite suppression, weight control, body fat decomposition, carbohydrate blocking and gastrointestinal activity modifiers such as fat absorption inhibition) drugsm traditational medicines, and diet supplement (including probiotics) the previous 6 months prior to Screening (reference to Prohibited Concomitant Substances) 3)the purpose of improving cholesterol and blood circulation drugs or diet supplement previous 3 months prior to Screening 4) physical examination and clinical examination have liver disorder , kidney disorder, pancreas disorder , biliary tract disorder , cardiovascular system disorder , respiratory system disorder , endocrine system disorder , and central nervous system disorders or malignant tumor (however, more than 5 years after surgery Participation is possible if it does not recur) 5)Those who have or have experience antipsychotic medication and psychotherapy for depression or other mental disorders 6)Those who have a medical history of clinically significant hypersensitivity reactions or have a possibility of hypersensitivity to raw materials and similar functional food of products for human application testing

Design outcomes

Primary

Measure	Time frame
Body Fat (kg,Percentage )	—

Secondary

Measure	Time frame
Weight Loss, BMI,Waist circumference;Change in level Adiponectin, Leptin;clinical laboratory tests (complete blood count (CBC), urinalysis, blood biochemistry, pregnancy test ;Lipid profile	—

Countries

Korea, Republic of

Contacts

Public ContactPark Nohwan

Korea National Sport University

sportsmania81@gmail.com+82-31-304-6118

Outcome results